Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Hoelscher

Internal Medicine Alton, IL Medical Doctor

NPI 1447267810 CMS profile 19858

2 Memorial Dr Ste 220, Alton, IL 62002

Open in the dashboard

General payments

$8,750

534 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Hoelscher of Alton, IL is reported in the CMS Open Payments database as having received $8,750 across 534 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $325 14
2024 General $1,288 67
2023 General $1,312 64
2022 General $632 35
2021 General $415 24
2020 General $2,262 142
2019 General $2,516 188

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Hoelscher
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to John Hoelscher were reported at $325. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year John Hoelscher Internal Medicine median Middle half National median
2019 $2,516 $159 $48–$570 $163
2020 $2,262 $119 $33–$402 $114
2021 $415 $135 $37–$521 $132
2022 $632 $141 $42–$496 $149
2023 $1,312 $149 $45–$519 $160
2024 $1,288 $154 $47–$537 $164
2025 $325 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $910 81 payments
  2. AbbVie, Inc. $832 41 payments
  3. Lilly USA, LLC $803 45 payments
  4. Amgen Inc. $782 43 payments
  5. Allergan Inc. $719 40 payments
  6. AstraZeneca Pharmaceuticals LP $711 39 payments
  7. Pfizer Inc. $514 40 payments
  8. GlaxoSmithKline, LLC. $494 32 payments
  9. Novartis Pharmaceuticals Corporation $324 18 payments
  10. Astellas Pharma US Inc $251 11 payments
  11. Other $2,410 144 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,550 529 payments
  2. Education $200 5 payments
Products named General payments · program years 2019–2025
  1. Ozempic $694 60 payments
  2. Prolia $608 33 payments
  3. EVENITY $586 32 payments
  4. UBRELVY Neuroscience $556 27 payments
  5. RYBELSUS $476 36 payments
  6. FARXIGA $462 27 payments
  7. MOUNJARO $454 21 payments
  8. UBRELVY Neuroscience $347 14 payments
  9. TRELEGY ELLIPTA $311 19 payments
  10. JARDIANCE $268 18 payments
  11. Other $7,141 455 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 232 drugs

Part D claims

24,427

Median for Internal Medicine: 777

Drug cost

$1,434,289

Median for Internal Medicine: $73,373

Branded share of claims

20.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 339 $319,439
Jardiance Empagliflozin Brand 139 $153,039
Ozempic Semaglutide Brand 137 $143,304
Glassia Alpha-1-Proteinase Inhibitor Brand 11 $114,657
Farxiga Dapagliflozin Propanediol Brand 106 $65,861
Entresto Sacubitril/Valsartan Brand 50 $40,923
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 50 $37,061
Mounjaro Tirzepatide Brand 25 $26,787
Xarelto Rivaroxaban Brand 17 $26,360
Januvia Sitagliptin Phosphate Brand 15 $23,872

The 10 drugs with the highest cost, of 232 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$235,192

Of which drugs: $63,616

Medicare patients

625

Average age 76

Services billed

5,744

343 women, 282 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 50%
Diabetes 26%
Ischemic heart disease 23%
Chronic kidney disease 22%
Depression 21%
Heart failure 19%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 17 1,560 $31,460
Pcv20 vaccine im 90677 Office 37 37 $10,789
Vaccine for influenza for injection into muscle 90662 Office 122 122 $9,942
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 45 $37

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $156
$156 25 —
ZEPBOUND
  • Lilly USA, LLC $76
$76 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $73
$73 50 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $68
$68 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $67
$67 106 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

534 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record